The Tufts Center for the Study of Drug Development is gathering new benchmark data on the vendor qualification process including the time, cost, and resources required to qualify contract service and technology vendors.
The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting an important new empirical study looking at the time and cost of the vendor qualification assessment process to all stakeholders involved—including those who issue RFIs/RFPs and conduct qualifications and those who respond to them. Tufts CSDD is hoping to gather a large robust global response. To complete a survey, please choose the appropriate questionnaire:
All responses are confidential and will only be presented in the aggregate - no individual or organization will be identified.
Tufts CSDD will send you a summary report of the results as a thank you for your participation.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.